The Food and Drug Administration on Friday approved Radicava — a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease.
Here are five things to know.
1. Radicava marks the first FDA-approved ALS treatment since riluzole hit the market in 1995, reports CNN.
2. The intravenous drug, developed by MT Pharma America, is administered daily in two-week treatment cycles.
3. The drug's list price is $1,000 per infusion, which totals nearly $150,000 annually, according to CNN.
4. Clinical trials conducted in Japan show patients taking Radicava had slower disease progression than those taking a placebo.
5. Jersey City, N.J.-based MT Pharma expects Radicava to hit the market in August.
More articles on supply chain:
Blue Cross member plans spent 73% more on drugs in 2016 than 2010
Supply chain tip of the week: Using the right equipment suppliers at the right time
Forget clothes — this thrift shop sells medical equipment